Down-regulation of immune checkpoints by doxorubicin and carboplatin-containing neoadjuvant regimens in a murine breast cancer model

  • سال انتشار: 1400
  • محل انتشار: مجله علوم پایه پزشکی ایران، دوره: 24، شماره: 4
  • کد COI اختصاصی: JR_IJBMS-24-4_016
  • زبان مقاله: انگلیسی
  • تعداد مشاهده: 469
دانلود فایل این مقاله

نویسندگان

Sanambar Sadighi

Department of Medical Oncology, Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran

Ramezanali Sharifian

Department of Hematology and Oncology, Vali-e-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran

Monireh Kazemimanesh

Department of Molecular Virology, Pasteur Institute of Iran, Tehran, Iran and Université Toulouse III Paul Sabatier, INSERM U۱۰۳۷, Cancer Research Centre of Toulouse (CRCT), Toulouse, France

Ahad Muhammadnejad

Cancer Biology Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences

Zahra Shohosseini

Department of Medical Biotechnology, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran

Saeid Amanpour

Cancer Biology Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences

Samad Muhammadnejad

Gene Therapy Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran

چکیده

Objective(s): Immune checkpoint expression on tumor-infiltrating lymphocytes (TILs) has a correlation with the outcome of neoadjuvant chemotherapy (NAC) in breast cancer. However, the reciprocal effect of these regimens on the quality and quantity of immune checkpoints has hitherto not been addressed. We aimed to evaluate the impact of three NAC regimens on TILs and immune checkpoints in a murine triple-negative breast cancer model.Materials and Methods: Syngeneic model of locally-advanced breast cancer was established in immunocompetent mice using a ۴T۱ cell line. Tumor-bearing animals were treated with human-equivalent dosages of doxorubicin, paclitaxel, paclitaxel and carboplatin combination, and placebo. Infiltration of CD۳+, CD۸+, and FoxP۳+ cells into the tumor was assessed by immunohistochemistry. Expression of immune checkpoints, including PD-۱, CTLA-۴, and TIM-۳, was evaluated by real-time PCR.Results: Doxorubicin led to a significant (p < ۰.۰۱) increase in the percentage of the stromal infiltrating CD۳+ and CD۸+ lymphocytes. Doxorubicin also suppressed significantly (p < ۰.۰۵) the relative expression of PD-۱ compared with the placebo. PD-۱ expression was significantly (p < ۰.۰۵) lower in the group treated with paclitaxel and carboplatin combination as compared with the placebo. The relative expression of TIM-۳ was significantly (p < ۰.۰۵) suppressed in doxorubicin-treated mice in comparison with other interventions.Conclusion: Our findings hypothesize that NAC with doxorubicin may potentiate antitumor immunity not merely by recruitment of TILs, but via down-regulation of PD-۱ and TIM-۳ checkpoints. Carboplatin-containing NAC may suppress PD-۱ as well.

کلیدواژه ها

Animal model Breast neoplasms Immune checkpoints Neoadjuvant chemotherapy Tumor, infiltrating, Lymphocytes

اطلاعات بیشتر در مورد COI

COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.

کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.